CRH Medical (CRHM) Downgraded by Zacks Investment Research to Hold

CRH Medical (NYSEAMERICAN:CRHM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “CRH Medical Corporation offers products and services to physicians for the treatment of gastrointestinal diseases primarily in the United States. The company provides the CRH O’Regan System, a single use, disposable and hemorrhoid banding technology for treating hemorrhoid grades I – IV. It distributes the CRH O’Regan System, treatment protocols, operational and marketing expertise as a complete, turnkey package directly to physicians. The company utilizes Web-based platform to connect doctors with patients as well as educating its install base of physicians. It also offers anesthesia services. CRH Medical Corporation is headquartered in Vancouver, Canada. “

Separately, Morgan Stanley upgraded CRH Medical from an “equal weight” rating to an “overweight” rating in a report on Friday, November 17th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. CRH Medical has a consensus rating of “Buy” and a consensus target price of $6.00.

CRH Medical (CRHM) opened at $2.65 on Monday. The company has a market capitalization of $200.14, a PE ratio of 37.86 and a beta of 1.29. CRH Medical has a twelve month low of $1.46 and a twelve month high of $9.25.

CRH Medical (NYSEAMERICAN:CRHM) last released its quarterly earnings data on Wednesday, November 1st. The company reported $0.03 EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.01). The firm had revenue of $23.35 million during the quarter, compared to the consensus estimate of $22.70 million.

A number of hedge funds and other institutional investors have recently modified their holdings of CRHM. Vanguard Group Inc. acquired a new stake in CRH Medical during the 2nd quarter valued at approximately $150,000. Advisor Group Inc. grew its stake in CRH Medical by 35.0% during the 2nd quarter. Advisor Group Inc. now owns 36,177 shares of the company’s stock valued at $206,000 after purchasing an additional 9,389 shares in the last quarter. PDT Partners LLC grew its stake in CRH Medical by 176.4% during the 2nd quarter. PDT Partners LLC now owns 50,162 shares of the company’s stock valued at $285,000 after purchasing an additional 32,013 shares in the last quarter. TD Asset Management Inc. grew its stake in CRH Medical by 65.3% during the 3rd quarter. TD Asset Management Inc. now owns 111,054 shares of the company’s stock valued at $289,000 after purchasing an additional 43,851 shares in the last quarter. Finally, Swiss National Bank acquired a new stake in CRH Medical during the 2nd quarter valued at approximately $709,000.

WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.com-unik.info/2018/01/17/crh-medical-crhm-downgraded-by-zacks-investment-research-to-hold.html.

CRH Medical Company Profile

CRH Medical Corporation is a Canada-based healthcare products and services company. The Company focused on providing physicians with services and products for the treatment of gastrointestinal diseases. The Company also provides anesthesiology services to gastroenterologists in the United States through its subsidiaries.

Get a free copy of the Zacks research report on CRH Medical (CRHM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for CRH Medical (NYSEAMERICAN:CRHM)

Receive News & Ratings for CRH Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRH Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit